RPO NucleoGenesis SRL
RPO NucleoGenesis reported total assets of 107,514 € at the end of the 2023 financial year (annual accounts filed with the NBB on 15 Jul 2024).
The score of RPO NucleoGenesis shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2023
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
RPO NucleoGenesis's annual accounts
| 2023 | |
|---|---|
| Net result | 2,885 € |
| Equity | 20,385 € |
| Cash | 96,962 € |
| EBITDA | 4,651 € |
| Total assets | 107,514 € |
Filed annual accounts
- Year ended 31 Dec 2023filed on 15 Jul 2024
RPO NucleoGenesis's financial analysis
- Solvency19.0%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of RPO NucleoGenesis
RPO NucleoGenesis's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0782.980.238
- VAT number
- BE0782980238
- Peppol
- Registered · 0208:0782980238 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Mar 2022
- Registered office
- 9031 Ghent
- Latest accounts
- 2023 · filed on 15 Jul 2024
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
RPO NucleoGenesis (SRL) has been based in Ghent since 2022, active in: manufacture of basic pharmaceutical products. For 2023, it reports a net profit of 2,885 € and equity of 20,385 €; its revenue is not published. Its solvency stands at 19.0%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to RPO NucleoGenesis
Companies in the same business, of comparable size and area, outside its group.
- Harika Lifij Manufacture of basic pharmaceutical products Evere · balance sheet 105,370 €
- Estrella Clinical Research Manufacture of basic pharmaceutical products Herentals · balance sheet 41,482 €
- Novozymatic Manufacture of basic pharmaceutical products Kapellen · balance sheet 148,440 €
- Evarmed Manufacture of basic pharmaceutical products Diepenbeek · balance sheet 51,346 €
- Santel Retail sale of pharmaceutical products Gerpinnes · balance sheet 146,637 €
- MDT Services & Technologies Manufacture of basic pharmaceutical products Lontzen · balance sheet 102,386 €
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Clinical Research Vanackere Manufacture of basic pharmaceutical products Tielt-Winge · balance sheet 263,927 €
Frequently asked questions about RPO NucleoGenesis
What is the revenue of RPO NucleoGenesis?
RPO NucleoGenesis files its accounts in a format where revenue is optional: it is not published for 2023.
What is the VAT number of RPO NucleoGenesis?
In Belgium, the VAT number is the company number prefixed with BE: BE0782980238 for RPO NucleoGenesis, if the company is VAT-registered. Its company number (CBE) is 0782.980.238.
Where is the registered office of RPO NucleoGenesis?
According to the CBE register, the registered office of RPO NucleoGenesis is in 9031 Ghent.
What is the equity of RPO NucleoGenesis?
At the close of the 2023 financial year, the equity of RPO NucleoGenesis amounts to 20,385 €, a solvency of 19.0% of total assets.
Who manages RPO NucleoGenesis?
The register lists 5 active mandates at RPO NucleoGenesis. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of RPO NucleoGenesis
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →